Similar articles

• A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.

  Smolenski C, Muff S, Smolenski-Kautz S. Smolenski C, et al. Curr Med Res Opin. 1981;7(6):374-83. Curr Med Res Opin. 1981. PMID: 7016449 Clinical Trial.
• Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity.

  Saltuari L, Kronenberg M, Marosi MJ, Kofler M, Russegger L, Rifici C, Bramanti P, Gerstenbrand F. Saltuari L, et al. Acta Neurol (Napoli). 1992 Jun;14(3):187-94. Acta Neurol (Napoli). 1992. PMID: 1442217 Clinical Trial.
• [Pharmacological treatment of pathological increases in muscle tonus].

  Reisner H. Reisner H. Wien Med Wochenschr. 1978 Feb 15;128(3):57-62. Wien Med Wochenschr. 1978. PMID: 625998 German. No abstract available.
• Intrathecal baclofen therapy for spastic hypertonia.

  Ivanhoe CB, Tilton AH, Francisco GE. Ivanhoe CB, et al. Phys Med Rehabil Clin N Am. 2001 Nov;12(4):923-38, viii-ix. Phys Med Rehabil Clin N Am. 2001. PMID: 11727722 Review.
• An approach to switching patients from baclofen to tizanidine.

  Brenner R, Hyman N, Knobler R, O'Brien M, Stephan T. Brenner R, et al. Hosp Med. 1998 Oct;59(10):778-82. Hosp Med. 1998. PMID: 9850294 Review.